Lapatinib plus transtuzumab for HER-2 positiva metastatic breast cancer: Experience of use
Abstract: Objective: To describe the outcomes produced by concomitant use of HER2-receptor inhibitors Lapatinib and Trastuzumab for the treatment of HER 2-positive metastatic breast cancer. Method: Retrospective observational study. Patients treated with Trastuzumab and Lapatinib between January o...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2014-03-01
|
| Series: | Farmacia Hospitalaria |
| Subjects: | |
| Online Access: | http://www.aulamedica.es/fh/pdf/1107.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850180728005853184 |
|---|---|
| author | C. García-Muñoz S. Cortijo-Cascajares I. Cañamares-Orbis M. P. Goyache-Goñi J. M. Ferrari-Piquero |
| author_facet | C. García-Muñoz S. Cortijo-Cascajares I. Cañamares-Orbis M. P. Goyache-Goñi J. M. Ferrari-Piquero |
| author_sort | C. García-Muñoz |
| collection | DOAJ |
| description | Abstract:
Objective: To describe the outcomes produced by concomitant use of HER2-receptor inhibitors Lapatinib and Trastuzumab for the treatment of HER 2-positive metastatic breast cancer.
Method: Retrospective observational study. Patients treated with Trastuzumab and Lapatinib between January of 2010 and May of 2012 were selected. Demographical and clinical data were gathered.
Results: 23 patients with metastatic breast cancer (mean age 59.3 ± 13.3 years) were included. All of them had received an average of 5 treatment lines with at least one of them including Trastuzumab. The median progression-free survival rate with combined Lapatinib + Trastuzumab, with or without associated chemotherapy was 7 months (95% CI: 2.78-11.21) and 3 months for the patients only receiving Lapatinib and Trastuzumab. Seven patients experienced adverse events and in four patients the treatment was stopped due to toxicity.
Conclusions: The treatment with HER2-receptor inhibitors in our patients resulted in progression-free survival rates similar to those published in clinical trials with patients receiving Lapatinib + Trastuzumab not combined with any other anti-cancer therapy, with good treatment tolerability. |
| format | Article |
| id | doaj-art-8c7d7767bc104650b09d691dbf677340 |
| institution | OA Journals |
| issn | 1130-6343 2171-8695 |
| language | English |
| publishDate | 2014-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Farmacia Hospitalaria |
| spelling | doaj-art-8c7d7767bc104650b09d691dbf6773402025-08-20T02:18:03ZengElsevierFarmacia Hospitalaria1130-63432171-86952014-03-0138213013410.7399/fh.2014.38.2.1107Lapatinib plus transtuzumab for HER-2 positiva metastatic breast cancer: Experience of useC. García-Muñoz0S. Cortijo-Cascajares1I. Cañamares-Orbis2M. P. Goyache-Goñi3J. M. Ferrari-Piquero4Servicio de Farmacia. Hospital Universitario 12 de Octubre. Madrid. España.Servicio de Farmacia. Hospital Universitario 12 de Octubre. Madrid. España.Servicio de Farmacia. Hospital Universitario 12 de Octubre. Madrid. España.Servicio de Farmacia. Hospital Universitario 12 de Octubre. Madrid. España.Servicio de Farmacia. Hospital Universitario 12 de Octubre. Madrid. España.Abstract: Objective: To describe the outcomes produced by concomitant use of HER2-receptor inhibitors Lapatinib and Trastuzumab for the treatment of HER 2-positive metastatic breast cancer. Method: Retrospective observational study. Patients treated with Trastuzumab and Lapatinib between January of 2010 and May of 2012 were selected. Demographical and clinical data were gathered. Results: 23 patients with metastatic breast cancer (mean age 59.3 ± 13.3 years) were included. All of them had received an average of 5 treatment lines with at least one of them including Trastuzumab. The median progression-free survival rate with combined Lapatinib + Trastuzumab, with or without associated chemotherapy was 7 months (95% CI: 2.78-11.21) and 3 months for the patients only receiving Lapatinib and Trastuzumab. Seven patients experienced adverse events and in four patients the treatment was stopped due to toxicity. Conclusions: The treatment with HER2-receptor inhibitors in our patients resulted in progression-free survival rates similar to those published in clinical trials with patients receiving Lapatinib + Trastuzumab not combined with any other anti-cancer therapy, with good treatment tolerability.http://www.aulamedica.es/fh/pdf/1107.pdfLapatinibTrastuzumabMetastatic breast cancerHER2 receptor |
| spellingShingle | C. García-Muñoz S. Cortijo-Cascajares I. Cañamares-Orbis M. P. Goyache-Goñi J. M. Ferrari-Piquero Lapatinib plus transtuzumab for HER-2 positiva metastatic breast cancer: Experience of use Farmacia Hospitalaria Lapatinib Trastuzumab Metastatic breast cancer HER2 receptor |
| title | Lapatinib plus transtuzumab for HER-2 positiva metastatic breast cancer: Experience of use |
| title_full | Lapatinib plus transtuzumab for HER-2 positiva metastatic breast cancer: Experience of use |
| title_fullStr | Lapatinib plus transtuzumab for HER-2 positiva metastatic breast cancer: Experience of use |
| title_full_unstemmed | Lapatinib plus transtuzumab for HER-2 positiva metastatic breast cancer: Experience of use |
| title_short | Lapatinib plus transtuzumab for HER-2 positiva metastatic breast cancer: Experience of use |
| title_sort | lapatinib plus transtuzumab for her 2 positiva metastatic breast cancer experience of use |
| topic | Lapatinib Trastuzumab Metastatic breast cancer HER2 receptor |
| url | http://www.aulamedica.es/fh/pdf/1107.pdf |
| work_keys_str_mv | AT cgarciamunoz lapatinibplustranstuzumabforher2positivametastaticbreastcancerexperienceofuse AT scortijocascajares lapatinibplustranstuzumabforher2positivametastaticbreastcancerexperienceofuse AT icanamaresorbis lapatinibplustranstuzumabforher2positivametastaticbreastcancerexperienceofuse AT mpgoyachegoni lapatinibplustranstuzumabforher2positivametastaticbreastcancerexperienceofuse AT jmferraripiquero lapatinibplustranstuzumabforher2positivametastaticbreastcancerexperienceofuse |